- Conditions
- Psoriasis
- Interventions
- CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo
- Drug
- Lead sponsor
- Janssen Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 924
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
- Interventions
- Pharmacokinetics of certolizumab pegol
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma
- Conditions
- Psoriasis, Alopecia Areata, Polymorphous Light Eruption
- Interventions
- Lumiton yarn sleeve, Lumiton yarn hat, Lumiton yarn shirt
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
- Interventions
- Resource sheets, Community Resource Specialist, Nurse Navigator
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Psoriasis
- Interventions
- Follow up from previous treatment with MEDI-507
- Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Alpharetta, Georgia + 4 more
- Conditions
- Plaque Psoriasis
- Interventions
- Zasocitinib, Deucravacitinib, Placebo to match zasocitinib, Placebo to match deucravacitinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 31
- States / cities
- Fort Smith, Arkansas • Hot Springs, Arkansas • Beverly Hills, California + 26 more
- Conditions
- Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
- Interventions
- Hypericin
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Psoriasis, Plaque Psoriasis
- Interventions
- ARQ-151 cream 0.3%
- Drug
- Lead sponsor
- Arcutis Biotherapeutics, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Mountain Brook, Alabama • Scottsdale, Arizona • Fountain Valley, California + 11 more
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
- Interventions
- Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
- Drug
- Lead sponsor
- Jeffrey Curtis
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 841 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
- Conditions
- Psoriasis, Aging, Epigenetic Disorder, Inflammation; Skin
- Interventions
- TILDRAKIZUMAB
- Biological
- Lead sponsor
- Carlos Wambier
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Psoriasis, Skin or Nails
- Interventions
- Excimer laser, Acitretin
- Device · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Psoriasis Vulgaris
- Interventions
- Active taVNS, Sham taVNS
- Device
- Lead sponsor
- Burrell College of Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Las Cruces, New Mexico
- Conditions
- Atopic Dermatitis, Psoriasis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- San Diego, California • Denver, Colorado
- Conditions
- Plaque Psoriasis
- Interventions
- CHS-1420, Adalimumab
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Encino, California • Sacramento, California + 23 more
- Conditions
- Psoriasis
- Interventions
- alefacept
- Biological
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- San Diego, California • Louisville, Kentucky
- Conditions
- Plaque Psoriasis
- Interventions
- Topical TA-102 A, Topical TA-102 B, Topical TA-102 C, Topical TA-102 D, Topical TA-102 E
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Plaque Psoriasis
- Interventions
- ORKA-001
- Drug
- Lead sponsor
- Oruka Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 20 more
- Conditions
- Psoriasis
- Interventions
- Transitioning patients from cyclosporine to alefacept
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- alefacept
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 11
- States / cities
- Hot Springs, Arkansas • Fridley, Minnesota • Omaha, Nebraska + 8 more
- Conditions
- Psoriasis
- Interventions
- NB-UVB Phototherapy
- Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Psoriasis
- Interventions
- Anecdotal Evidence, Research Study Evidence, Anecdotal + Research Study Evidence, No Evidence
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Plaque Psoriasis, Skin Diseases, Papulosquamous, Skin Diseases
- Interventions
- AM001 Cream, 7.5%, Placebo of AM001 Cream
- Drug
- Lead sponsor
- AmDerma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Miami, Florida • Fridley, Minnesota • Albuquerque, New Mexico + 2 more
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Bimekizumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 11
- States / cities
- Fremont, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Psoriasis
- Interventions
- risankizumab, secukinumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 28
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 24 more